Long-term follow-up of people treated for early choroidal melanoma in the CoMpass trial
Follows adults with early choroidal melanoma who finished the earlier bel-sar trial.
Plain-language title generated from the registry record
Registry title: A Long-Term Follow-Up Study of Subjects Completing the AU-011-301(CoMpass) for Early Choroidal Melanoma
Key facts
- Where
- Berlin, Essen, Hamburg, and Munich, GermanySee the 4 sites
- Phase
- Phase 3
Where in Germany
- Charite Universitaetsmedizin Berlin KöRBerlin, GermanyNot yet recruiting
- Universitaetsklinikum Essen (AoR)Essen, GermanyNot yet recruiting
- University Medical Center Hamburg-EppendorfHamburg, GermanyNot yet recruiting
- LMU Klinikum Muenchen AöRMunich, GermanyNot yet recruiting
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Aura Biosciences
- Trial code
- NCT07338968EU 2025-524405-33-00
- Record updated
- 19 August 2026
- Original description
AU-011-403 is a multicenter long-term follow-up safety and efficacy study of subjects with early CM who previously participated in the AU-011-301 Phase 3 trial. There are no required interventions or use of AU-011 (bel-sar) in this long-term follow-up studyRead full original descriptionShow less
A Long-Term Follow-Up Study of Subjects Completing the AU-011-301 (CoMpass) Trial of Bel-sar for Early Choroidal Melanoma (Indeterminate Lesions/Small Choroidal Melanomas)
AU-011-403 is a multicenter long-term follow-up safety and efficacy study of subjects with early CM who previously participated in the AU-011-301 Phase 3 trial. There are no required interventions or use of AU-011 (bel-sar) in this long-term follow-up study
Inclusion: Have received bel-sar or sham treatment in the Aura-sponsored clinical trial AU-011-301; Be willing and able to consent to the AU-011-403 study.
Exclusion: None.